Publication analysis · Module 9
EVOKE: mechanism and clinical progression
The phase 3 evoke and evoke+ trials studied oral semaglutide in early symptomatic Alzheimer’s disease. The primary endpoint measured clinical progression using CDR-SB at 104 weeks. Semaglutide did not slow that progression compared with placebo.
Original publication
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+)
DOI 10.1016/S0140-6736(26)00459-9 · PMID 41865758 · Citation pending verification
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
The phase 3 evoke and evoke+ trials studied oral semaglutide in early symptomatic Alzheimer’s disease. The primary endpoint measured clinical progression using CDR-SB at 104 weeks. Semaglutide did not slow that progression compared with placebo.
A plausible mechanism or a favorable biomarker cannot replace the prespecified clinical result. This example shows why evidence of biological activity must be distinguished from evidence of patient benefit. It does not establish the effectiveness of another peptide, a combination, or a different preventive strategy.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
Related resources
Publication analysis · Module 9
MOTS-c and exercise: keep the human and animal experiments separate
This paper combines human exercise measurements with experimental MOTS-c administration in animals. Changes in endogenous MOTS-c after human exercise and animal performance findings are distinct results. The human component is not a trial demonstrating that injected MOTS-c reproduces exercise benefits in people.
Publication analysis · Module 1
STEP 1: what a weight-management trial can establish
STEP 1 randomized 1,961 adults with overweight or obesity, without diabetes, to subcutaneous semaglutide or placebo with lifestyle support for 68 weeks. Mean weight change was −14.9% versus −2.4%. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%. The study was funded by Novo Nordisk.
Publication analysis · Module 3
SURMOUNT-1: interpreting a multigroup obesity trial
SURMOUNT-1 randomized 2,539 adults with overweight or obesity, excluding diabetes, to three weekly tirzepatide groups or placebo for 72 weeks. Mean weight changes were −15.0%, −19.5%, and −20.9% in the 5-, 10-, and 15-mg study groups, respectively, versus −3.1% with placebo. These amounts identify trial groups, not an administration recommendation.